Artificial intelligence has moved from the margins of vaccinology to the centre of the discovery pipeline — predicting targets, designing molecules and modelling immune responses long before a single dose is made. This briefing summarises where the science stands, what it delivers, who is investing, and how the market is expected to grow.
Figures are third-party market-research projections and vary between sources; they are indicative rather than definitive. Sources are listed at the foot of this page.
Traditional vaccine development is slow, costly and largely empirical — researchers screen large numbers of pathogen proteins in the laboratory, often with a low hit rate, and a candidate can take many years to travel from bench to clinic. Artificial intelligence changes the economics of that search. By learning from large biological datasets, modern models can predict which parts of a pathogen are most likely to provoke a protective immune response, design the molecule that presents them, and simulate the likely outcome before any wet-lab work begins.
The term “AI vaccine” is therefore best understood not as a new type of vaccine but as a new method of creating them — one that now spans every major platform, from protein-subunit and viral-vector vaccines to the mRNA approach proven at scale during the COVID-19 pandemic.
Empirical screening of many pathogen proteins, lengthy iterative laboratory work, high attrition, and development timelines measured in years.
Computational prediction of promising targets, in-silico design and simulation, fewer and better-aimed experiments, and a faster, lower-risk route into clinical trials.
Across academia and industry, AI is now embedded at multiple points in the vaccine pipeline — antigen and epitope prediction, immunogen and protein design, mRNA optimisation, clinical-trial data mining and efficacy modelling. A few areas illustrate how far the field has moved.
Deep-learning models — convolutional networks, transformers and graph neural networks — now predict which peptides the immune system will recognise. One 2025 model trained on more than 650,000 human HLA–peptide interactions identified viral targets with accuracy rivalling laboratory binding assays, suggesting AI can replace some early wet-lab screens.
Structure-prediction systems such as AlphaFold, including the diffusion-based AlphaFold 3, model how antigens and antibodies interact. Researchers have used these tools to design self-assembling protein-nanoparticle immunogens from scratch, with a designed influenza candidate eliciting strong neutralising antibodies in animal studies.
Generative and reinforcement-learning methods now propose entirely new candidate sequences optimised for immune recognition. In one 2025 approach, the great majority of AI-generated peptides validated experimentally showed improved binding, and several triggered measurable T-cell responses.
AI is central to bespoke mRNA cancer vaccines, sifting a patient’s tumour mutations to pick the best targets. A leading personalised candidate combined with an immunotherapy reported a roughly 49% reduction in the risk of melanoma recurrence or death in a mid-stage trial and has advanced into Phase III.
Industry has followed the science closely. Major manufacturers have woven AI through both the front end (antigen design and immune-response prediction) and the back end (virtual screening of candidates and faster discovery), and a computationally designed protein-nanoparticle COVID-19 vaccine has already been licensed in several countries — an early proof point that AI-designed components can reach the clinic.
The value of AI in this field is practical rather than abstract. It concentrates on the slowest, most expensive and most failure-prone parts of vaccine development.
AI-driven vaccine work sits inside two overlapping growth stories: the broad expansion of vaccines as a category, and the much faster growth of AI applied to their development. Market-research estimates differ in their exact numbers, but all point in the same direction — strong, sustained growth.
| Segment | Indicative size & horizon | Growth |
|---|---|---|
| AI for vaccine development | ~$12bn (2023) → ~$119bn (2030) | ~39% CAGR |
| Vaccine technologies | ~$50bn (2024) → ~$155bn (2035) | ~11% CAGR |
| Global vaccine market (all) | ~$87bn (2024) → ~$197bn (2035) | ~8% CAGR |
Estimates compiled from several third-party market-research publishers; treat as indicative projections, not guarantees.
For all its momentum, AI is an accelerant for vaccine development, not a replacement for it. Several caveats temper the enthusiasm and are worth holding in mind.
Validation still rules. A predicted antigen is a hypothesis; safety and efficacy are still established through laboratory work and clinical trials. AI shortens the path to a good candidate but does not remove the regulatory and biological hurdles that follow.
Data and reliability. Models are only as good as the immunological data they learn from, and they can “hallucinate” in poorly understood regions of a protein. Interpretability — understanding why a model made a prediction — remains an active and important research area.
Ethics and governance. Personalised and rapidly generated vaccines raise questions about data privacy, equitable access and how regulators assess AI-designed products. These will shape how quickly the science reaches patients.
The direction of travel, however, is clear. As datasets grow, generative and multi-modal models mature, and more AI-designed candidates clear the clinic, the role of artificial intelligence in vaccinology is set to deepen — making the design of safe, effective and even individualised vaccines faster and more achievable than at any point in the field’s history.